West Pharmaceutical Services Stock News

EXTON, Pa., March 9, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will part

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

If history is any guide, there may be trouble ahead for shares … Full story available on Benzinga.com

Hyderabad: West Pharmaceutical Services, which operates in injectable drug administration segment, appointed Ravikrishna Chebolu as GM of its India operations. While Wests global headquarter is in Exton, Pennsylvania, United States, in India the company has its sales office in Hyderabad, servicing customers throughout India. With over 20 years of relevant commercial and general management experience []

WST earnings call for the period ending December 31, 2021.

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q4 2021 Results - Earnings Call Transcript

West Pharmaceutical Services Inc''s (NYSE: WST ) Q4 net sales increased 26% Y/Y to $730.8 million , beating the consensus of $710.20 million. Organic sales growth was 28.3%. Q4 FY21 EPS reached $2.04 from $1.34 a year ago, surpassing the consensus of $1.91. Gross profit increased from 36.4% to 41.1%. Adjusted operating profit margin reached … Full story available on Benzinga.com

West Pharmaceutical press release (WST): Q4 Non-GAAP EPS of $2.04 beats by $0.12.Revenue of $730.8M (+26.0% Y/Y) beats by $20.6M.Company is introducing full-year 2022 financial…

West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.

West Pharmaceutical (WST) delivered earnings and revenue surprises of 6.25% and 3.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical (NYSE:WST) is scheduled to announce Q4 earnings on Thursday, Feb. 17, before market open.The consensus EPS estimate is $1.92 (+43.3% Y/Y)

West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.